Ronda W. Morris

- Data from mouse models in hereditary tyrosinemia type 1 and Wilson's disease showed that the modified hepatocytes in vivo expanded and significantly repopulated diseased livers, correlating with improved disease burdenPosted: October 21,!-->…

- Funding co-led by Pfizer Ventures and EcoR1 Capital with participation from a syndicate of world-class life sciences investors- Company to Advance mRNA and Gene Correction Therapies in Cystic Fibrosis and Primary Ciliary Dyskinesia…

CAMBRIDGE, Mass., October 21, 2021 (GLOBE NEWSWIRE) - Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage genome editing company focused on developing curative treatments using CRISPR / Cas9 technology at the times in vivo…

Gangnam Severance Hospital said a new calorie-restricted Korean-style Mediterranean diet (KMD) developed by its researchers has helped reduce cardiovascular risk by improving chronic inflammation, insulin resistance and fatty liver…

Statins decrease the production of LDL cholesterol, also known as “bad cholesterol” in the liver. Patients with heart disease can also take statins to prevent other risks. Hepatitis is one of the rarer side effects of statins. This can…

AnnMarie Liapakis to be honored as transplant 'superhero'AnnMarie Liapakis, MD, associate professor of medicine (digestive diseases) and surgery (transplant); and Medical Director, Living Donor Liver Transplantation, is honored Nov. 18 by…

Representative image | Photo: Express On Wednesday, October 20, a doctor specializing in hepatology and liver transplant medicine addressed the Kerala High Court challenging the…

As a month with trees full of colors, October represents Breast and Liver Cancer Awareness Month, dedicated to raising awareness of breast and liver cancer and raising funds for research into its cause, prevention, diagnosis, treatment and…

University of Queensland start-up developing a potential new treatment for obesity-related liver disease has secured an initial investment of $ 1.3 million from IP Group, an intellectual property company based UK.Jetra Therapeutics Pty Ltd…

Since its first approval in 2017, more than 100,000 patients have been treated with AstraZeneca Imfinzi's monoclonal antibody (durvalumab), primarily in non-small cell lung cancer.However, new data from the ongoing HIMALAYA Phase 3 trial…